Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28071053 | 1.00 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL14653343 | 1.00 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| Hydrochloric Acid SCHEMBL29057157 | 0.98 | USP2 (0.55) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL17297711 | 0.98 | USP2 (0.55) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL587550 | 0.98 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL12005408 | 0.98 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL1225127 | 0.98 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL8286 | 0.98 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| Ammonia Solution, Strong SCHEMBL18035416 | 0.96 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL2220355 | 0.96 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678227-B | Treatment of cancer cells overexpressing somatostatin receptors using octreotide derivatives chelated with radioisotopes | 雷迪奥梅迪克斯股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-110678227-A | Treatment of cancer cells overexpressing somatostatin receptors using octreotide derivatives chelated with radioisotopes | 雷迪奥梅迪克斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-9115094-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) (US) | 2015-08-25 | — | — | US | disclosed |
| US-8501398-B2 | Luminescence assay using macrocyclic lanthanide (III) complexes | UNIVERSITY OF DURHAM (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2041571-B1 | LUMINESCENCE ASSAY USING MACROCYCLIC LANTHANIDE (III) COMPLEXES | UNIV DURHAM (GB) | 2010-09-15 | — | — | EP | disclosed |
| CN-101732730-A | Cation lipid containing imidazolium salt and macrocyclic polyamines, transgenetic vector and method for preparing same | UNIV SICHUAN | 2010-06-16 | — | — | CN | disclosed |
| US-20100055665-A1 | LUMINESCENCE ASSAY USING MACROCYCLIC LANTHANIDE (III) COMPLEXES | UNIVERSITY OF DURHAM (GB) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, PKD1 | USP2 2745/4885SMN1; SMN2 2566/4885MAPK1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.